Consistent with published data demonstrating that a NOS inhibitor decreased KRAS-driven NSCLC tumour growth and synergized with chemotherapy45, combination of l-NMMA with cisplatin/etoposide delayed tumour growth and significantly increased event-free survival in CDX17P. This evidence concerns the gene KRAS and neoplasm.